Acta Med. 2016, 59: 54-58

https://doi.org/10.14712/18059694.2016.54

Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer

Martin Beráneka,b,*, Igor Sirákc, Milan Vošmikc, Jiří Peterac, Monika Drastíkováb, Vladimír Paličkab

aDepartment of Biochemical Sciences, Charles University, Faculty of Pharmacy in Hradec Králové, Czech Republic
bInstitute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
cDepartment of Oncology, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic

Received February 10, 2016
Accepted April 18, 2016

The aims of the study were: i) to compare circulating tumor DNA (ctDNA) yields obtained by different manual extraction procedures, ii) to evaluate the addition of various carrier molecules into the plasma to improve ctDNA extraction recovery, and iii) to use next generation sequencing (NGS) technology to analyze KRAS, BRAF, and NRAS somatic mutations in ctDNA from patients with metastatic colorectal cancer. Venous blood was obtained from patients who suffered from metastatic colorectal carcinoma. For plasma ctDNA extraction, the following carriers were tested: carrier RNA, polyadenylic acid, glycogen, linear acrylamide, yeast tRNA, salmon sperm DNA, and herring sperm DNA. Each extract was characterized by quantitative real-time PCR and next generation sequencing. The addition of polyadenylic acid had a significant positive effect on the amount of ctDNA eluted. The sequencing data revealed five cases of ctDNA mutated in KRAS and one patient with a BRAF mutation. An agreement of 86% was found between tumor tissues and ctDNA. Testing somatic mutations in ctDNA seems to be a promising tool to monitor dynamically changing genotypes of tumor cells circulating in the body. The optimized process of ctDNA extraction should help to obtain more reliable sequencing data in patients with metastatic colorectal cancer.

Funding

The study was supported by the project MZ CR – RVO (FNHK, 00179906) of the Ministry of Health, Czech Republic, and by the projects PRVOUK P37/11 and P37/09 of the Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic.

References

29 live references